Scholarlink

<p>This real-world study from southern China retrospectively evaluated the effectiveness, tolerability, and retention of low-dose perampanel (PER 2–6&#xa0;mg) in focal epilepsy and explored associated clinical factors. Based on the steady-state maintenance dose of PER (2, 4, or 6&#xa0;mg/day), 190 patients were enrolled from July 2020 to August 2023. Outcomes included seizure reduction, responder rates (≥ 50% reduction), adverse events (AEs), and retention at 3, 6, 9, and 12 months. At 12 months, seizure frequency reductions were 100% (2&#xa0;mg), 91% (4&#xa0;mg), and 82.5% (6&#xa0;mg). Efficacy rates at 12 months were 44.6% (2&#xa0;mg), 50% (4&#xa0;mg), and 66.8% (6&#xa0;mg) (<i>P</i> = 0.168). Exploratory analyses suggested a higher responder rate with 6&#xa0;mg versus 2&#xa0;mg in patients with disease duration ≥ 5 years or focal seizures only (<i>P</i> = 0.023; <i>P</i> = 0.044). Multivariable analysis indicated that a lower number of concomitant ASMs was independently associated with better early response (6-month), while a shorter disease duration (&lt; 5 years) was associated with better long-term (12-month) response, independent of the specific dose within the 2–6&#xa0;mg range. AE incidence was lowest with 2&#xa0;mg (14.3%) versus 4&#xa0;mg (24.1%) and 6&#xa0;mg (23.9%). Respective 12-month retention rates were 32.2, 46.8, and 58.6%. In conclusion, this study suggests that low-dose PER (2–6&#xa0;mg) can achieve favorable short- and long-term seizure control in focal epilepsy patients aged ≥ 12 years, with a good tolerability profile. The benefits were particularly pronounced in those with a shorter disease duration (&lt; 5 years) and those receiving monotherapy or early add-on therapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effectiveness of low-dose perampanel in focal epilepsy patients aged twelve or older in Southern China: an observational study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月24日

查看全文
  • Xiangru Lu,
  • Yuwen Deng,
  • Xiaoli Shi,
  • Yongfeng Feng,
  • Jinou Zheng,
  • Yuan Wu,
  • Lu Yu

摘要

This real-world study from southern China retrospectively evaluated the effectiveness, tolerability, and retention of low-dose perampanel (PER 2–6 mg) in focal epilepsy and explored associated clinical factors. Based on the steady-state maintenance dose of PER (2, 4, or 6 mg/day), 190 patients were enrolled from July 2020 to August 2023. Outcomes included seizure reduction, responder rates (≥ 50% reduction), adverse events (AEs), and retention at 3, 6, 9, and 12 months. At 12 months, seizure frequency reductions were 100% (2 mg), 91% (4 mg), and 82.5% (6 mg). Efficacy rates at 12 months were 44.6% (2 mg), 50% (4 mg), and 66.8% (6 mg) (P = 0.168). Exploratory analyses suggested a higher responder rate with 6 mg versus 2 mg in patients with disease duration ≥ 5 years or focal seizures only (P = 0.023; P = 0.044). Multivariable analysis indicated that a lower number of concomitant ASMs was independently associated with better early response (6-month), while a shorter disease duration (< 5 years) was associated with better long-term (12-month) response, independent of the specific dose within the 2–6 mg range. AE incidence was lowest with 2 mg (14.3%) versus 4 mg (24.1%) and 6 mg (23.9%). Respective 12-month retention rates were 32.2, 46.8, and 58.6%. In conclusion, this study suggests that low-dose PER (2–6 mg) can achieve favorable short- and long-term seizure control in focal epilepsy patients aged ≥ 12 years, with a good tolerability profile. The benefits were particularly pronounced in those with a shorter disease duration (< 5 years) and those receiving monotherapy or early add-on therapy.